Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25308285 | 0.89 | NR4A2 (0.62) | NR4A2ALDH1A1KMT2AGABRA1GABRB1 | |
| SCHEMBL26261523 | 0.89 | NR4A2 (0.62) | NR4A2ALDH1A1KMT2AGABRA1GABRB1 | |
| SCHEMBL29647632 | 0.89 | NR4A2 (0.62) | NR4A2ALDH1A1KMT2AGABRA1GABRB1 | |
| SCHEMBL26261556 | 0.89 | NR4A2 (0.62) | NR4A2ALDH1A1KMT2AGABRA1GABRB1 | |
| Hydrochloric Acid SCHEMBL25262906 | 0.88 | NR4A2 (0.60) | NR4A2ALDH1A1KMT2AGABRA1GABRB1 | |
| SCHEMBL3174938 | 0.85 | NR4A2 (0.49) | NR4A2CHRNB2CHRNA7CHRNA4ALDH1A1 | |
| SCHEMBL25742139 | 0.85 | NR4A2 (0.45) | NR4A2CHRNB2CHRNA7CHRNA4ALDH1A1 | |
| SCHEMBL25742053 | 0.83 | NR4A2 (0.62) | NR4A2ALDH1A1KMT2A | |
| SCHEMBL25742185 | 0.83 | KMT2A (0.43) | NR4A2ALDH1A1KMT2ATUBB1 | |
| SCHEMBL25742050 | 0.83 | GPR84 (0.45) | NR4A2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257347-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257347-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2023107715-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257347-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | HTR6, TPH2, TPH1 | NR4A2 1706/4885CHRNB2 112/4885CHRNA7 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.